Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Rating) CEO Steven A. Shallcross acquired 25,000 shares of the firm's stock in a transaction on Wednesday, January 25th. The stock was purchased at an average cost of $0.87 per share, with a total value of $21,750.00. Following the purchase, the chief executive officer now owns 160,000 shares of the company's stock, valued at $139,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Theriva Biologics Stock Performance
Shares of NYSEAMERICAN TOVX opened at $0.90 on Friday. Theriva Biologics, Inc. has a 1 year low of $0.39 and a 1 year high of $4.39.
Get Theriva Biologics alerts:About Theriva Biologics
(Get Rating)
Theriva Biologics, Inc is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C.Further Reading
- Get a free copy of the StockNews.com research report on Theriva Biologics (TOVX)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.